Altimmune (ALT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist

6.490
+0.250+4.01%

Close Aug 16 16:00 ET

6.574
+0.084+1.30%

Post 19:59 ET

461.25MMarket Cap-3981P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
BenzingaAug 12 14:44 ET
Altimmune Analyst Ratings
BenzingaAug 12 14:43 ET · Ratings
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
TipRanksAug 12 12:35 ET · Ratings
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Earnings Call TranscriptsAug 10 09:03 ET
Evercore ISI Remains a Buy on Altimmune (ALT)
TipRanksAug 9 09:53 ET · Ratings
Altimmune, Inc. (ALT): A Good GLP-1 and Weight Loss Stock to Buy Now?
Yahoo FinanceAug 8 20:15 ET

Comments

frogoracletrading

Yesterday 08:29

$ALT Support / Resistance Levels

After consolidating in the POC for several days ALT has broken over the 6.45 resistance. Next stop is 6.77 if it continues up.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

NEWS

$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...